Skip to content

Abdominal Nerve Blockade in Chronic Heart Failure.

Splanchnic Nerve Blockade in Chronic Heart Failure. Splanchnic CHF

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03453151
Enrollment
19
Registered
2018-03-05
Start date
2018-05-01
Completion date
2019-12-27
Last updated
2020-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Patients with chronic heart failure and undergoing right heart catheterization will be enrolled in this study. Subjects will undergo catheterization of the heart to obtain central cardiac pressure and other cardiac hemodynamic parameters. Subsequently, the subject will undergo a regional nerve block of the splanchnic nerves. This study will be a prospective, uncontrolled clinical trial. The study will not be controlled as invasive monitoring of hemodynamics will be performed, allowing clear demonstration of a cause-effect relationship. The goal of the study is to provide proof of concept. Patients will undergo detailed physiological testing.

Interventions

regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of heart failure (HF) * Symptomatic with dyspnea * On a stable HF drug regimen

Exclusion criteria

* Ongoing treatment with oral anticoagulation other than aspirin * Immunosuppressive medications for solid organ transplant * Acute MI (STEMI or Type I NSTEMI) within 7 days * Systolic blood pressure \< 90 mmHg or \>180 mmHg * Infiltrative cardiomyopathy or constrictive cardiomyopathy * Chronic kidney disease stage 5 * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary Capillary Wedge Pressure (PCWP)baseline, up to 1 hourPulmonary capillary wedge pressure will be measured at 20 Watts steady state and peak exercise.
Exercise Capacity as Measured by Peak Oxygen Uptake (Peak VO2)baseline, up to 1 hourPeak VO2 will be measured before and after nerve block.
Mean Pulmonary Arterial Pressure (mPAP)baseline, up to 1 hourMean pulmonary arterial pressure will be measured before and after nerve block.

Secondary

MeasureTime frameDescription
Cardiac Index (CI)baseline, up to 1 hourCardiac index will be measured at 20 Watts steady state and peak exercise. Cardiac index (CI) is a haemodynamic parameter that relates the cardiac output (CO) from left ventricle in one minute to body surface area (BSA), thus relating heart performance to the size of the individual.
Urine Output2 hours pre-SNB, 2 hours post-SNBUrine output will be measured in the 2 hours before the nerve block and in the 2 hours afterwards
Renal Biomarker Levels2 hours pre-SNB, 2 hours post-SNBBUN (blood urea nitrogen) and creatinine levels will be measured in the 2 hours before the nerve block and in the 2 hours afterwards.

Countries

United States

Participant flow

Participants by arm

ArmCount
Splanchnic Nerve Block (SNB)
Splanchnic nerve anesthesia with a local anesthetic: regional nerve block with a local anesthetic (Lidocaine/Ropivacaine)
15
Total15

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision3
Overall StudyWithdrawal by Subject1

Baseline characteristics

CharacteristicSplanchnic Nerve Block (SNB)
Age, Continuous58 years
STANDARD_DEVIATION 13
N terminal pro BNP (B-type natriuretic peptide) level2172 pmol/L
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
3 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
12 Participants
Region of Enrollment
United States
15 Participants
Sex: Female, Male
Female
7 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 15
other
Total, other adverse events
5 / 15
serious
Total, serious adverse events
0 / 15

Outcome results

Primary

Exercise Capacity as Measured by Peak Oxygen Uptake (Peak VO2)

Peak VO2 will be measured before and after nerve block.

Time frame: baseline, up to 1 hour

ArmMeasureGroupValue (MEAN)Dispersion
Splanchnic Nerve Block (SNB)Exercise Capacity as Measured by Peak Oxygen Uptake (Peak VO2)Before nerve block9.1 mL/kg/minStandard Deviation 2.5
Splanchnic Nerve Block (SNB)Exercise Capacity as Measured by Peak Oxygen Uptake (Peak VO2)After nerve block9.8 mL/kg/minStandard Deviation 2.7
p-value: 0.053Paired t-test
Primary

Mean Pulmonary Arterial Pressure (mPAP)

Mean pulmonary arterial pressure will be measured before and after nerve block.

Time frame: baseline, up to 1 hour

ArmMeasureGroupValue (MEAN)Dispersion
Splanchnic Nerve Block (SNB)Mean Pulmonary Arterial Pressure (mPAP)Before nerve block40.5 mmHgStandard Deviation 12.3
Splanchnic Nerve Block (SNB)Mean Pulmonary Arterial Pressure (mPAP)After nerve block32.7 mmHgStandard Deviation 13.8
p-value: <0.001Paired t-test
Primary

Pulmonary Capillary Wedge Pressure (PCWP)

Pulmonary capillary wedge pressure will be measured at 20 Watts steady state and peak exercise.

Time frame: baseline, up to 1 hour

ArmMeasureGroupValue (MEAN)Dispersion
Splanchnic Nerve Block (SNB)Pulmonary Capillary Wedge Pressure (PCWP)Steady state, before nerve block28.3 mmHgStandard Deviation 7.6
Splanchnic Nerve Block (SNB)Pulmonary Capillary Wedge Pressure (PCWP)Steady state, after nerve block20.3 mmHgStandard Deviation 9.5
Splanchnic Nerve Block (SNB)Pulmonary Capillary Wedge Pressure (PCWP)Peak exercise, before nerve block34.8 mmHgStandard Deviation 10
Splanchnic Nerve Block (SNB)Pulmonary Capillary Wedge Pressure (PCWP)Peak exercise, after nerve block25.1 mmHgStandard Deviation 10.7
p-value: <0.001Paired t-test
Secondary

Cardiac Index (CI)

Cardiac index will be measured at 20 Watts steady state and peak exercise. Cardiac index (CI) is a haemodynamic parameter that relates the cardiac output (CO) from left ventricle in one minute to body surface area (BSA), thus relating heart performance to the size of the individual.

Time frame: baseline, up to 1 hour

ArmMeasureGroupValue (MEAN)Dispersion
Splanchnic Nerve Block (SNB)Cardiac Index (CI)Steady state, before nerve block1.9 L/min/m^2Standard Deviation 0.6
Splanchnic Nerve Block (SNB)Cardiac Index (CI)Steady state, after nerve block2.3 L/min/m^2Standard Deviation 0.7
Splanchnic Nerve Block (SNB)Cardiac Index (CI)Peak exercise, before nerve block3.4 L/min/m^2Standard Deviation 1.2
Splanchnic Nerve Block (SNB)Cardiac Index (CI)Peak exercise, after nerve block3.8 L/min/m^2Standard Deviation 1.1
p-value: 0.077Paired t-test
p-value: 0.069Paired t-test
Secondary

Renal Biomarker Levels

BUN (blood urea nitrogen) and creatinine levels will be measured in the 2 hours before the nerve block and in the 2 hours afterwards.

Time frame: 2 hours pre-SNB, 2 hours post-SNB

ArmMeasureGroupValue (MEAN)Dispersion
Splanchnic Nerve Block (SNB)Renal Biomarker LevelsCreatinine, before nerve block1.2 mg/dLStandard Deviation 0.4
Splanchnic Nerve Block (SNB)Renal Biomarker LevelsCreatinine, after nerve block1.2 mg/dLStandard Deviation 0.4
Splanchnic Nerve Block (SNB)Renal Biomarker LevelsBUN, before nerve block19 mg/dLStandard Deviation 10
Splanchnic Nerve Block (SNB)Renal Biomarker LevelsBUN, after nerve block18 mg/dLStandard Deviation 10
p-value: 0.25Paired t-test
p-value: 0.014Paired t-test
Secondary

Urine Output

Urine output will be measured in the 2 hours before the nerve block and in the 2 hours afterwards

Time frame: 2 hours pre-SNB, 2 hours post-SNB

ArmMeasureGroupValue (MEAN)Dispersion
Splanchnic Nerve Block (SNB)Urine OutputBefore nerve block167 mLStandard Deviation 174
Splanchnic Nerve Block (SNB)Urine OutputAfter nerve block297 mLStandard Deviation 180

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026